Evotec SE (OTCPK:EVOTF) Q4 2022 Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - Royal Bank of Canada Peter Verdult - Citi James Quigley - Morgan Stanley Steven Mah - Cowen Peter Welford - Jefferies Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator L ...

Evotec SE (OTCPK:EVOTF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets Christian Ehmann - Warburg Research James Quigley - Morgan Stanley Derik de Bruin - Bank of America Peter Welford - Jefferies Joe Hedde ...

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT 9M 2022 HIGHLIGHTS EVOTEC'S TOPLINE SUCCESS REFLECTS STRONG OVERALL DEMAND SHARED R&D PLATFORMS FOR HIGHER PROBABILITIES OF SUCCESS (POS) 2 4 MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS 4 PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY 4 COMMERCIAL LAUNCH OF NEXT-GENERAT ...

Evotec SE (OTCPK:EVOTF) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants | --- | |------------------------------------------------| | | | Dr. Werner Lanthaler - Chief Executive Officer | | Enno Spillner - Chief Financial Officer | | Cord Dohrmann - Chief Scientific Officer | | Craig Johnstone - Chief Operating Officer | | Matthias Evers - Chief Business Officer | | Conference Call Participants | | | | Zoe Karamanoli - RBC Capital Markets | | James Quigley - Morgan Stanley | | ...

| --- | --- | |---------------------------------------------------|-------| | | | | Accelerating precision medicine | | | Evotec SE, H1 2022 Interim Report, 11 August 2022 | | Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "b ...

Exhibit 99.1 volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com #RESEARCHNEVERSTOPS HALF-YEAR REPORT 2022 Half-year Interim Report PUBLICATION DATE: 11 AUGUST 2022 -- For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, HALF-YEAR REPORT 2022 I. MANAGEMENT REPORT 4 NEW AND EXTENDED ALLIANCES UNDERLINE SUCCESS OF GROWTH STRATEGY 4 ACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPY 4 GUIDANCE FOR FULL-YEAR 2022 RE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ Form 20-F ___________________________ (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...

Evotec SE (NASDAQ:EVO) Q4 2021 Earnings Conference Call April 12, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chairman and Chief Executive Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Enno Spillner - Chief Financial Officer Conference Call Participants James Quigley - Morgan Stanley Joseph Hedden - Rx Securities Falko Friedrichs - Deutsche Bank Igor Kim - Berenberg Michael Ryskin - Bank of America Zoe Karamanoli - RBC Capital Markets Operator Dear la ...

Financial Data and Key Metrics Changes - The company reported a 17% increase in revenue for H1 2021, with a strong 27% organic growth when adjusted for foreign exchange and portfolio effects [13] - Gross margin decreased to 20.8% from 23% year-on-year, primarily due to the end of the Sanofi subsidy for the Toulouse site [14] - R&D expenses increased by 90% compared to last year, driven by enhancements to multiple platforms and the co-owned pipeline [14] - Net income for H1 2021 amounted to €111.9 million, benefiting from a positive one-off effect from the fair value upgrade of the Exscientia/Evo equity engagement [17] Business Line Data and Key Metrics Changes - Execute revenues grew by 18% year-to-date, driven by increasing demand for integrated offerings and a strong base business [21] - Innovate revenues reached €57.3 million, a 27% increase, reflecting high demand for precision medicine and new partnerships [22] - Innovate's adjusted EBITDA was negative at €15.7 million, primarily due to increased R&D and SG&A investments [23] Market Data and Key Metrics Changes - The company experienced a negative currency effect of €11.5 million due to a weakened US dollar against the euro [25] - The order books are at record levels, indicating strong long-term demand across all offerings [11] Company Strategy and Development Direction - The company aims to create the largest royalty pool in the industry by co-owning valuable assets, with a focus on long-term value creation [44] - The J.POD initiative is a strategic response to the anticipated global shortage of biologics capacity, with plans for expansion in both the US and Europe [42][71] - The company is committed to integrating AI and machine learning across various modalities, enhancing productivity and precision in drug discovery [61][64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the second half of 2021, anticipating substantial additional income from milestones originally expected in Q2 [20] - The company is closely monitoring inflation and input costs but currently does not expect immediate impacts due to strong stock levels and increased buying power [81] - The company confirmed its guidance for 2021, expecting strong news flow and a top line of €550 million to €570 million [57] Other Important Information - The company is pursuing a dual listing on NASDAQ to increase engagement with US institutional investors and support growth initiatives [35][86] - The company is actively involved in social responsibility initiatives, particularly in response to the COVID-19 pandemic, aiming to improve access to therapeutics globally [50][101] Q&A Session Summary Question: Trends in AI-based drug discovery and Evotec's positioning - The company applies machine learning across various modalities, leveraging data from top pharma and biotech partners to enhance productivity [61][62] Question: Cold Spring Harbor lab collaboration focus - The collaboration aims to translate ideas across all modalities, not limited to biologics [66] Question: Timeline for J.POD 1 manufacturing capacity - Full capacity for the first two trains is expected within the next 24 months, driven by business demand [70] Question: Guidance on adjusted EBITDA - The company is optimistic about the second half due to expected data points and novel transactions, despite the inherent volatility of milestone payments [76][78] Question: Update on Phase III compound with JingXin - JingXin has accelerated recruitment for their clinical trial, and the company remains optimistic about their progress [80] Question: NASDAQ listing expectations - The dual listing aims to increase visibility and attract US-based investors, with no urgent financing pressure [86][87] Question: Protein degradation agreement with BMS - The company is actively involved in protein degradation and has expanded its partnership with BMS into new disease areas [95][96]

Financial Performance H1 2021 - Group revenues increased by 17% to €2713 million (H1 2020: €2310 million), with organic growth at a record level of 27%[11] - Adjusted Group EBITDA decreased by 23% to €362 million (H1 2020: €473 million), mainly due to planned capacity build-up ahead of the imminent production start of J·POD® 1 US, like-for-like growth was 13%[11] - Expenses for unpartnered R&D increased by 29% to €278 million (H1 2020: €216 million)[11] - Net income increased significantly by over 100% to €1127 million (H1 2020: €73 million), benefiting from the fair value adjustment of EVO equity investment Exscientia[18] - Base revenues increased by 17% or €381 million to €2613 million, with Just – Evotec Biologics adding revenues of €230 million, an increase of 44%[20] Guidance and Outlook - The company confirmed its 2021 outlook, projecting Group revenues of €550-570 million (2020: €5009 million) and adjusted Group EBITDA of €105-120 million (2020: €1066 million)[11] - Unpartnered R&D expenses are expected to be €50-60 million (2020: €464 million)[11] - Action Plan 2025 targets were confirmed, aiming for revenues > €1000 million, adjusted EBITDA ≥ €300 million, and unpartnered R&D > €100 million[11] Strategic Developments - The acquisition of the Verona site from GlaxoSmithKline SpA was completed, now named "Campus Levi-Montalcini"[10, 35, 37] - A significant extension of the BMS Oncology protein degradation partnership was achieved ahead of term, along with a new protein degradation collaboration in an undisclosed therapeutic area also signed with BMS[10, 46] - J·POD® 1 US in Redmond is opening on August 18th, and construction of J·POD® 2 EU is set to start in Q4 2021[10] - The company submitted a registration statement for a proposed offering of American Depositary Shares (after period-end)[10]